Medios : Company presentation

Creating the leading European Specialty Pharma Platform

Company Presentation

March, 2024

Every day > 60.000 people are diagnosed with life-threatening diseases1

At Medios, we are dedicated to timely providing high-quality and efficient treatments to patients with complex diseases

1 Globally; Sources: https://www.unaids.org/en/resources/fact-sheet,https://www.who.int/campaigns/world-hepatitis-day/2021,https://wfh.org/article/wbdr-2022-data-report-published/,https://www.who.int/news/item/03-02-2022-world-cancer-day-closing-the-care-gap;

Diseases: Cancer, hemophilia, HIV, hepatitis.	2

[Specialty Pharma] Complex and cost-intensivetreatment of life-threatening,chronic or rare diseases

e.g. Cancer, hemophilia, HIV, hepatitis

3

"We are creating the leading European Specialty Pharma platform to treat diseases optimally with individualized medicine."

Matthias Gärtner, CEO Medios AG

4

"I work for Medios because I can contribute to patient care that meets the highest quality standards."

1 Medios at a Glance

2 Key Investment Highlights

3 Financials FY 2023

4 Outlook Appendix

5

Medios at a Glance

The leading provider of Specialty Pharma in Germany

#1 in Specialty Pharma

~€1.8bn

Revenue 2023

Partner network

~800

Partner

Pharmacies

Nationwide coverage

with 6 GMP Labs & 2 Warehouses

Highly

Diversified

6

Indications for complex diseases

Comprehensive expertise

512 Employees1

Clear focus

1,000

Specialty Pharmaceuticals

Only Specialty Pharma company listed on FSE2

since 2016

Quality and efficiency

~400,000

Individual Preparations 2023

Status: March 2024 1Average employees I 2FSE = Frankfurt Stock Exchange (Prime Standard), I 3Depending on indications

6

PATIENT-SPECIFIC THERAPIES

Pharmaceutical compounding

of patient-specific therapies

PHARMACEUTICAL SUPPLY

Pharmaceutical supply of

finished Specialty Pharma

medications

Medios at a Glance

Integrated platform for

Specialty Pharma

• Strategic cross-selling with broad range of indications
• Partner for changing standard and individualized therapies
• Ensuring highest quality standards through integrated nationwide platform of GMP1 and GDP2 facilities
• Efficiency and accessibility due to proven supply network

1 GMP = Good manufacturing practice I 2 GDP = Good distribution practice	7

Medios at a Glance

From a local player to the #1 in Specialty Pharma in Germany

7-fold

Growth of revenue within just 6 years

21.3% p.a.

Organic growth since 2017

#1

In Specialty Pharma via organic growth and M&A

> €2.15bn

Revenue ambition (Outlook 2025)

Revenue (in €m)

		CAGR:
		~38%
254	328	517	627	1,357	1,610	1,785
2017	2018	2019	2020	2021	2022	2023

8

Medios at a Glance

Strong financial results in 2023

~€1.8bn ~€60.5m

+10.8%+10.3%

Net EBITDA

Revenue pre1

Ongoing		2.5€		Low CAPEX
positive		+10.1%
operating		EBITDA pre1		~€1.3m
cash flow		per share

1 EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2023 additionally for one-time	9
performance-based payments for the acquisition of manufacturing volumes

Medios at a Glance

Clear strategy to build the leading European Specialty Pharma Platform

Building

the leading

European Specialty Pharma Platform

Continue evolving our Specialty Pharma business in Germany

Expand compounding within Europe to gain continued growth, while increasing profitability

Become a trusted partner for manufacturing of advanced therapies

Target for 2025

• €2.15bn Revenue
• €110m EBITDA pre1
• 5.1% EBITDA pre1 margin

1 EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and for one-timeperformance-based payments for the

acquisition of compounding volumes as well as from expenses for ERP-System implementation.

10